Medline Inc. MDLN

Medline Inc.’s latest supplied financial rail is led by its official SEC EDGAR 10-Q for the period ending 2026-03-28: revenues of $7.35B, operating income of $422.0M, diluted EPS of $0.16 and operating cash flow of $412.0M. The same evidence set also includes six June 17, 2026 Form 4 filings on SEC EDGAR, plus 8-K filings dated 2026-06-12 and 2026-06-02.

The company story in this pack is concrete healthcare supply, not a loose market label. The 10-Q evidence names Prime Vendor customers, Medline Brand products, Supply Chain Solutions third-party sales, Surgical Solutions, operating room products and kitting products. That matters because the filing ties revenue movement to customer volume and product mix rather than leaving the reader with a bare ticker and a price chart.

The filed figures give the report its backbone. Medline reported assets of $39.01B, liabilities of $19.66B, stockholders’ equity attributable to parent of $11.27B and cash and cash equivalents of $2.24B in the 10-Q period ending 2026-03-28. Inventory, net, was $4.81B, with an increase in inventories of $42.0M. Payments to acquire property, plant and equipment were $96.0M. Research and development expense was $80.0M in the 10-K period ending 2025-12-31.

No chart route or price-level evidence is supplied in this rail, so the market mechanism here is filing-led rather than candle-led. The available sources are official SEC EDGAR pages, the SEC submissions JSON, the SEC companyfacts JSON, the 10-Q, the two 8-K filings and the credit agreement amendment dated 2026-05-28. That limits the report to documented operating facts, balance sheet facts and named filing developments.

What changed inside the operating story is the mix. The 10-Q evidence says Prime Vendor sales of Medline Brand products rose $152M, or 10.5%, to $1.605B for the three months ended 2026-03-28 versus the respective period in 2025. Surgical Solutions net sales rose $107M, or 7.4%, to $1.554B, primarily driven by volume growth in operating room and kitting products. The same filing evidence says gross profit margin was hurt by sales to new Prime Vendor customers that typically have lower margins in early periods, while increased sales to existing Prime Vendor customers helped.

What remains unproven is just as important. The supplied rail does not provide share price action, trading volume, guidance, dividend policy, buyback activity, analyst commentary or a fresh management call transcript. The cleaner next layer would be a source-backed bridge from these SEC filings to current market pricing, but that bridge is not in today’s evidence.